Illinois Court Dismisses Antitrust Case Against Biogen Over Tecfidera Pricing

In a recent development, an Illinois federal court has dismissed a proposed class action against Biogen, concerning its multiple sclerosis medication, Tecfidera. The lawsuit accused Biogen of engaging in anti-competitive practices by making payments to pharmacy benefit managers, allegedly affecting drug pricing lists. However, the judge determined that only specific pricing lists were potentially influenced, leading to the case’s dismissal, for the present time. For further details, refer to the original article.